2023년 9월 연구원 논문
김순찬 연구조교수 (허혈저산소질환연구소)
Patient-derived glioblastoma cell lines with conserved genome profiles of the original tissue
Scientific data
Glioblastoma (GBM) is the most lethal intracranial tumor. Sequencing technologies have supported
personalized therapy for precise diagnosis and optimal treatment of GBM by revealing clinically
actionable molecular characteristics. Although accumulating sequence data from brain tumors and
matched normal tissues have facilitated a comprehensive understanding of genomic features of GBM,
these in silico evaluations could gain more biological credibility when they are verified with in vitro and
in vivo models. From this perspective, GBM cell lines with whole exome sequencing (WES) datasets
of matched tumor tissues and normal blood are suitable biological platforms to not only investigate
molecular markers of GBM but also validate the applicability of druggable targets. Here, we provide a
complete WES dataset of 26 GBM patient-derived cell lines along with their matched tumor tissues and
blood to demonstrate that cell lines can mostly recapitulate genomic profiles of original tumors such as
mutational signatures and copy number alterations.
